Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ: INCY )

72.19 -0.28 (-0.39%)
Streaming Delayed Price Updated: 1:49 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China
Incyte Corporation (NASDAQ: INCY) and InnoCare have entered into a collaboration and license agreement to develop and commercial tafasitamab in Greater... 
Via Benzinga
Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China
From Incyte
Via Business Wire
BriaCell Therapeutics Attacks Cancer with Novel Off-the-Shelf Immunotherapies
Photo by Chokniti Khongchum from Pexels In 2020, there were 2.3 million women globally diagnosed with breast cancer and 685,000 deaths, according to the World Health Organization... 
Via Benzinga
Topics Death
Exposures Death
Is the PD-(L)1 Party Over After Incyte's FDA Rejection?
There's definitely already a crowded market for PD-1 and PD-L1 immunotherapies. 
Via The Motley Fool
Exposures Product Safety
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Lows On Tuesday
Before 10 a.m. ET on Tuesday, 60 companies set new 52-week lows. Key Facts: PACCAR (NASDAQ:PCAR) was the biggest company by market cap to set a new 52-week low.... 
Via Benzinga
Incyte Corporation (INCY) Q2 2021 Earnings Call Transcript
INCY earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
A Perspective On The Upcoming Calithera Cystic Fibrosis Read-Out
Calithera is guiding for the market to expect what we believe will be a key data read-out in Q3 from its ongoing CB-280 study involving Cystic Fibrosis. A positive read-out here could see a significant... 
Via Talk Markets
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi... 
Via Benzinga
A Preview Of Incyte's Earnings
Incyte (NASDAQ:INCY) will be releasing its next round of earnings this Tuesday, August 03. For all of the relevant information, here is your guide for Tuesday's Q2 earnings... 
Via Benzinga
2 Stocks Under $100 You Can Buy and Hold Forever
Drugmakers can be excellent long-term holdings. 
Via The Motley Fool
Eli Lilly-Incyte's Rheumatoid Arthritis Drug Gets OK From FDA For Solo Use In Hospitalized COVID-19 Patients
The FDA extended the Emergency Use Authorization (EUA) for Eli Lilly And Co's (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) rheumatoid... 
Via Benzinga
Exposures COVID-19 Product Safety
FDA Strikes Off Incyte's Retifanlimab Application In Anal Cancer
The 
Via Benzinga
Exposures Product Safety
Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
From Incyte Corporation
Via Business Wire
Benchmark Upgrades Incyte After Stock Selloff
The recent downturn in Incyte Corporation’s (NASDAQ:INCY... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021
Upgrades For Bank of Marin Bancorp (NASDAQ: 
Via Benzinga
AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA
AbbVie Inc (NYSE: ABBV) and Eli Lilly And Co (NYSE: LLY) will have to keep waiting for a chance for their JAK inhibitors in atopic dermatitis to see the market.... 
Via Benzinga
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,... 
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Incyte's Ruxolitinib Shows Better Outcomes Regardless Of Organs Affected In GvHD Patients
Incyte Corporation (NASDAQ: INCY) has announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM... 
Via Benzinga
Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease
From Incyte
Via Business Wire
BriaCell's Early-Stage Combination Study In Advanced Breast Cancer Starts Enrollment
BriaCell Therapeutics Corp (NASDAQ: BCTX) has opened recruitment and enrollment of their collaborative clinical study with Incyte Corporation (NASDAQ:... 
Via Benzinga
Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer
The National Medical Products Administration (NMPA) of China has accepted for review Innovent Biologics Inc's (OTC: IVBIY) marketing application seeking... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive... 
Via Benzinga
EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters
The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug for an initial... 
Via Benzinga
Exposures COVID-19
FDA AdCom In Favor Of Delaying Incyte's Retifanlimab Approval In Anal Cancer
Members of the Oncologic Drugs Advisory Committee 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.